Alume Biosciences, Inc.

Alume Biosciences, Inc. is a US-based company focused on precision surgical solutions, utilizing innovative technology to enhance visibility of nerves during surgery, thereby improving surgical outcomes. Founded in 2017 and headquartered in San Diego, California, Alume Biosciences, Inc. specializes in nerve illumination technologies.

The company has engaged in five significant deals, with its most recent funding round being a Series B that raised USD 12. 76 mn on December 28, 2022, bringing its total amount raised to USD 12. 76 mn and current valuation to USD 172. 569 mn.

The founding team includes Brett Berman, Chrysa Mineo, Mike Whitney, and Quyen Nguyen, who serves as the CEO. Alume Biosciences specializes in precision surgical solutions through its flagship product, ALM-488, which is designed to illuminate nerves during surgical procedures. Administered via IV to patients 60 minutes prior to surgery, ALM-488 enhances the visibility of nerves, aiding surgeons in preserving nerve function during operations. This innovative technology targets critical use cases, such as minimizing nerve damage in procedures that could impact mobility and sensation.

The primary end users of Alume's products include surgical teams and hospitals, particularly within the fields of neurosurgery and orthopedic surgery. Alume Biosciences operates within the United States market while also working towards expanding its offerings to international healthcare systems as clinical trials progress. Alume Biosciences generates revenue through direct sales of ALM-488 to healthcare providers and surgical facilities engaged in advanced surgical practices. The transaction structure typically involves B2B partnerships, where hospitals and surgical centers procure the product for use in operating rooms.

Pricing plans are designed to accommodate the varying scales of healthcare providers, with bulk purchasing options available for larger facilities. The company is currently conducting Phase 3 clinical trials aimed at FDA submission in 2025, which may further enhance its market presence and revenue potential as clinical adoption increases. Overall, the revenue model is closely linked to the efficacy and demand for nerve illumination technology in surgical applications. In December 2022, Alume Biosciences, Inc.

raised USD 12. 76 million in Series B funding from unspecified investors. The company will use the funding to accelerate its lead candidate, Bevonescein (ALM-488), in Phase 3 clinical trials. Alume is also targeting expansion into international markets, aiming to extend its reach beyond the United States healthcare systems as clinical trials progress.